# A Long-term Follow-up Study in Patients Who Received BEAM-101

> **NCT07373639** · — · RECRUITING · sponsor: **Beam Therapeutics Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Hemoglobinopathy
- Sickle Cell Disease

## Interventions

- **DRUG:** Long-Term Follow-up Study of patients who received BEAM-101

## Key facts

- **NCT ID:** NCT07373639
- **Lead sponsor:** Beam Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-15
- **Primary completion:** 2043-02-12
- **Final completion:** 2043-02-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07373639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07373639, "A Long-term Follow-up Study in Patients Who Received BEAM-101". Retrieved via AI Analytics 2026-09-17 from https://api.ai-analytics.org/clinical/NCT07373639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*